Alty Matthew sold $3.9M of LYNX
Alty Matthew (President) sold 238,583 shares of Lyntris Inc. (LYNX) at $16.45 ($3.92M total) on 2026-08-20.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, which some traders view as a bearish cue.
Market read
The filing provides fresh insider‑sale data that may influence short‑term trading decisions.
What to watch
No accompanying corporate news; the insider may be diversifying without loss of confidence.
Background
SEC Form 4 filings disclose insider transactions; they are primary sources for insider activity.
Ticker impact
President Alty Matthew sold 238,583 shares for $3.9M, reducing his stake to 1.79M shares.
Potential modest dip of 1‑2% over the next few days.
A $3.9M open‑market sale by a senior officer is material for a mid‑cap, but the amount is not large enough to trigger a sharp move.
Market effects
Minimal; the sale does not affect the broader sector.
None; the filing is U.S. specific.
Low; only relevant to Lyntris shareholders.
Counterpoint
The sale could be a routine liquidity event, not a negative signal.
Key entities
- CompanyLyntris Inc.
Public biotech firm listed under ticker LYNX.
- IndividualAlty Matthew
President and director of Lyntris.